Stem cell factor (SCF) is an important growth factor for multiple cell types. Research has shown that SCF is expressed in glioma cells and as a result of various types of brain injury, but its significance is not fully understood. Dr. Howard A. Fine from the National Cancer Institute/National Institute of Neurological Disorders and Stroke at the National Institutes of Health and colleagues designed a study to investigate whether, as a result of tumor-induced brain injury, brain cell-mediated SCF expression contributes to tumor growth by setting up an environment that supports angiogenesis and tumor progression.
The researchers demonstrate that decreased SCF expression in vivo results in decreased angiogenesis and improved survival in mouse glioma models, whereas overexpression of SCF is associated with a worse prognosis and shorter survival in patients with glioblastomas. SCF expression is not directly linked to tumor cell proliferation but instead encourages the growth of blood vessels needed to support the expanding tumor. Importantly, these findings provide definitive evidence that factors promoting tumor progression extend beyond the tumor itself and involve a complex interaction between the cancer cells and the normal cells that are perturbed by expanding tumor.
These results suggest that SCF is a potent glioma-associated angiogenic factor that plays a prominent role in pathological angiogenesis both through direct tumor cell expression of SCF and by normal neurons that are damaged by the gr owing tumor. The researchers point out that the clinical significance of these findings extends beyond identification of SCF as a rational target for gliomas. "Normal neuronal expression of SCF in response to traumatic brain injury also raises the disturbing possibility that standard invasive procedures such as surgical biopsies or partial tumor resections may be inducing a proangiogenic response, or trigger, within the brain," cautions Dr. Fine.